奥沙利铂诱导的免疫性溶血性贫血：一例报告及文献复习

Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.

作者信息

Cobo Francesc, De Celis Guillem, Pereira Arturo, Latorre Xavier, Pujadas Jaume, Albiol Santiago

机构信息

Oncohematology Unit, Hospital Ntra. Sra. De Meritxell, Escaldes-Engordany, Andorra.

出版信息

Anticancer Drugs. 2007 Sep;18(8):973-6. doi: 10.1097/CAD.0b013e3280e9496d.

DOI:10.1097/CAD.0b013e3280e9496d

PMID:17667605

Abstract

We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil). Immunohematologic studies demonstrated that immune hemolysis was oxaliplatin-mediated. On the basis of this case and in a review of the literature in which 13 cases of previously reported oxaliplatin-induced immune cytopenia have been identified, we suggest some clinical clues regarding the use of oxaliplatin in cancer patients.

摘要

我们报告了一名59岁被诊断为转移性结直肠癌的女性患者，她在接受FOLFOX化疗（奥沙利铂/亚叶酸钙/5-氟尿嘧啶）期间发生了免疫性溶血性贫血。免疫血液学研究表明，免疫溶血是由奥沙利铂介导的。基于该病例以及对文献的回顾（其中已确定13例先前报道的奥沙利铂诱导的免疫性血细胞减少症），我们提出了一些关于癌症患者使用奥沙利铂的临床线索。